HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Correspondence: View responses Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ficker, D. M. Articles by Glauser, T. Search for Related Content PubMed PubMed Citation Articles by Ficker, D. M. Articles by Glauser, T. Related Collections All Clinical trials Clinical trials Observational study (Cohort, Case control) All Epilepsy/Seizures Antiepileptic drugs

Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine

From the Department of Neurology (Drs. Ficker and Privitera), University of Cincinnati Medical Center, OH; Department of Neurology (Dr. Krauss), Johns Hopkins University School of Medicine, Baltimore, MD; Rush Epilepsy Center and Department of Neurological Sciences (Dr. Kanner), Rush Medical College, Chicago, IL; Department of Neurology and College of Pharmacy (Dr. Moore), The Ohio State University, Columbus; and Department of Neurology (Dr. Glauser), Children’s Hospital Medical Center, Cincinnati, OH.

Address correspondence and reprint requests to Dr. David Ficker, Department of Neurology, University of Cincinnati Medical Center, 231 Albert B. Sabin Way, Cincinnati, OH 45267; e-mail: david.ficker{at}uc.edu

The authors conducted a 3-month, prospective, open-label study assessing the effects of switching from immediate-release carbamazepine formulations to an equal total daily dose of carbamazepine extended-release capsules (CBZ-ERC) in adolescents and adults with epilepsy. Using validated, epilepsy-specific measures the authors found that switching to CBZ-ERC significantly improved patients’ adverse events and quality-of-life measures. Switching to CBZ-ERC also improved seizure control.

Supported by Shire. Carbatrol is a registered trademark of Shire.

Disclosure: D.M. Ficker, MD, M. Privitera, MD, G. Krauss, MD, A Kanner, MD, J.L. Moore, MD, and T. Glauser, MD, received honoraria from the study sponsor. Shire funded the study and was responsible for the design and conduct of the study, and collection, management, and analysis of the data.

Received November 30, 2004. Accepted in final form May 4, 2005.

This article has been cited by other articles:

				S. Perry, P. Holt, and M. Benatar Levetiracetam Versus Carbamazepine Monotherapy for Partial Epilepsy in Children Less Than 16 Years of Age J Child Neurol, May 1, 2008; 23(5): 515 - 519. [Abstract] [PDF]

				A. Verrotti, C. Salladini, G. Di Marco, F. Pisciella, and F. Chiarelli Extended-Release Formulations in Epilepsy J Child Neurol, April 1, 2007; 22(4): 419 - 426. [Abstract] [PDF]

				M. J. Brodie, E. Perucca, P. Ryvlin, E. Ben-Menachem, H.-J Meencke, and for the Levetiracetam Monotherapy Study Group Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy Neurology, February 6, 2007; 68(6): 402 - 408. [Abstract] [Full Text] [PDF]

				P. Ryvlin, A. Montavont, and N. Nighoghossian Optimizing therapy of seizures in stroke patients Neurology, December 26, 2006; 67(12_suppl_4): S3 - S9. [Abstract] [Full Text]

				L. M. Protass and D. M. Ficker Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine Neurology, March 28, 2006; 66(6): 957 - 957. [Full Text] [PDF]

Correspondence: